Hehlmann et al. abstract
Please cite this article as follows: Hehlmann R, Saußele S. Integration of leukemia research in Europe: the paradigm CML. Cell Ther Transplant. 2008;1:e.000015.01. doi:10.3205/ctt-2008-en-000015.01
Integration of leukemia research in Europe: the paradigm CML1
R. Hehlmann, S. Saußele
1Presented at the 2nd Raissa Gorbacheva Memorial Symposium in St. Petersburg, Russia, on 20 September 2008
Abstract
Leukemias are rare diseases, the investigation into which requires multicenter activities, study groups and networking. The ELN integrates leukemia research and trial groups across Europe. Progress with CML continues to promote European integration (EUTOS for CML). Median survival with CML is now expected at 25 years. The main treatment options for CML are TK inhibition and allo-SCT. Treatment optimization trials are ongoing worldwide. Looking at the speed of current progress, the prospects for a cure of CML, and possibly other forms of leukemia, are good.
Keywords: chronic myeloid leukemia, BCR-ABL, tyrosine kinase, inhibitors, clinical response, comparative trials, European Leukemia Network
Please cite this article as follows: Hehlmann R, Saußele S. Integration of leukemia research in Europe: the paradigm CML. Cell Ther Transplant. 2008;1:e.000015.01. doi:10.3205/ctt-2008-en-000015.01
Full text
<-- Previous abstract Contents
<-- Предыдущее резюме Oглавление
